JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marier, J.-F.
Right arrow Articles by Ducharme, M. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marier, J.-F.
Right arrow Articles by Ducharme, M. P.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Vol. 302, Issue 1, 369-373, July 2002

Metabolism and Disposition of Resveratrol in Rats: Extent of Absorption, Glucuronidation, and Enterohepatic Recirculation Evidenced by a Linked-Rat Model

Jean-Francois Marier , Pascal Vachon, Ari Gritsas, Jie Zhang, Jean-Pierre Moreau and Murray P. Ducharme

MDS Pharma Services, Montreal, Quebec, Canada (J.-F.M., A.G., J.Z., J.-P.M., M.P.D.); and Faculté de Pharmacie, University of Montreal, Montreal, Quebec, Canada (J.-F.M., P.V., M.P.D.)

Pharmacokinetics of trans-resveratrol in its aglycone (RESAGL) and glucuronide (RESGLU) forms were studied following intravenous (15 mg/kg i.v.) and oral (50 mg/kg p.o.) administration of trans-resveratrol in a solution of beta -cyclodextrin to intact rats. In addition, the enterohepatic recirculation of RESAGL and RESGLU was assessed in a linked-rat model. Multiple plasma and urine samples were collected and concentrations of RESAGL and RESGLU were determined using an electrospray ionization-liquid chromatography/tandem mass spectrometry method. After i.v. administration, plasma concentrations of RESAGL declined with a rapid elimination half-life (T1/2, 0.13 h), followed by sudden increases in plasma concentrations 4 to 8 h after drug administration. These plasma concentrations resulted in a significant prolongation of the terminal elimination half-life of RESAGL (T1/2TER, 1.31 h). RESAGL and RESGLU also displayed sudden increases in plasma concentrations 4 to 8 h after oral administration, with T1/2TER of 1.48 and 1.58 h, respectively. RESAGL bioavailability was 38% and its exposure was approximately 46-fold lower than that of RESGLU (AUCinf, 7.1 versus 324.7 µmol·h/l). Enterohepatic recirculation was confirmed in the linked-rat model since significant plasma concentrations of RESAGL and RESGLU were observed in bile-recipient rats at 4 to 8 h. The percentages of the exposures of RESAGL and RESGLU that were due to enterohepatic recirculation were 24.7 and 24.0%, respectively. The fraction of drug excreted in the urine over a period of 12 h was negligible. These results confirm that RESAGL is bioavailable and undergoes extensive first-pass glucuronidation, and that enterohepatic recirculation contributes significantly to the exposure of RESAGL and RESGLU in rats.

0022-3565/02/3021-0369$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 FASEB J.Home page
C. M. Klinge, N. S. Wickramasinghe, M. M. Ivanova, and S. M. Dougherty
Resveratrol stimulates nitric oxide production by increasing estrogen receptor {alpha}-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells
FASEB J, July 1, 2008; 22(7): 2185 - 2197.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
O. F. Iwuchukwu and S. Nagar
Resveratrol (trans-Resveratrol, 3,5,4'-Trihydroxy-trans-stilbene) Glucuronidation Exhibits Atypical Enzyme Kinetics in Various Protein Sources
Drug Metab. Dispos., February 1, 2008; 36(2): 322 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
D. J. Boocock, G. E.S. Faust, K. R. Patel, A. M. Schinas, V. A. Brown, M. P. Ducharme, T. D. Booth, J. A. Crowell, M. Perloff, A. J. Gescher, et al.
Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent
Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1246 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. Lancon, N. Hanet, B. Jannin, D. Delmas, J.-M. Heydel, G. Lizard, M.-C. Chagnon, Y. Artur, and N. Latruffe
Resveratrol in Human Hepatoma HepG2 Cells: Metabolism and Inducibility of Detoxifying Enzymes
Drug Metab. Dispos., May 1, 2007; 35(5): 699 - 703.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Urpi-Sarda, R. Zamora-Ros, R. Lamuela-Raventos, A. Cherubini, O. Jauregui, R. de la Torre, M. I. Covas, R. Estruch, W. Jaeger, and C. Andres-Lacueva
HPLC-Tandem Mass Spectrometric Method to Characterize Resveratrol Metabolism in Humans
Clin. Chem., February 1, 2007; 53(2): 292 - 299.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Boissy, T. L. Andersen, B. M. Abdallah, M. Kassem, T. Plesner, and J.-M. Delaisse
Resveratrol Inhibits Myeloma Cell Growth, Prevents Osteoclast Formation, and Promotes Osteoblast Differentiation
Cancer Res., November 1, 2005; 65(21): 9943 - 9952.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. M. Klinge, K. A. Blankenship, K. E. Risinger, S. Bhatnagar, E. L. Noisin, W. K. Sumanasekera, L. Zhao, D. M. Brey, and R. S. Keynton
Resveratrol and Estradiol Rapidly Activate MAPK Signaling through Estrogen Receptors {alpha} and {beta} in Endothelial Cells
J. Biol. Chem., March 4, 2005; 280(9): 7460 - 7468.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Z.-H. Chen, Y.-J. Hurh, H.-K. Na, J.-H. Kim, Y.-J. Chun, D.-H. Kim, K.-S. Kang, M.-H. Cho, and Y.-J. Surh
Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells
Carcinogenesis, October 1, 2004; 25(10): 2005 - 2013.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
A. J. Gescher and W. P. Steward
Relationship between Mechanisms, Bioavailibility, and Preclinical Chemopreventive Efficacy of Resveratrol: A Conundrum
Cancer Epidemiol. Biomarkers Prev., October 1, 2003; 12(10): 953 - 957.
[Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.